Evidence map›Paper›PMID 30153863›Full record

ArticleAlzheimer's research & therapy2018

Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer's disease.

Piotr Lewczuk, Amélie Gaignaux, Olga Kofanova, Natalia Ermann, Fay Betsou, Sebastian Brandner, Barbara Mroczko, Kaj Blennow, Dominik Strapagiel, Silvia Paciotti and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Combination of plasma amyloid betaAlzheimer's research & therapy · 2020
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 7 countries.

Piotr LewczukDepartment of Psychiatry and Psychotherapy, Laboratory for Clinical Neurochemistry and Neurochemical Dementia Diagnostics, Universitätsklinikum Erlangen, and Friedrich-Alexander Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Germany. Piotr.Lewczuk@uk-erlangen.de.ORCID 0000-0002-8101-6535
Amélie GaignauxIntegrated BioBank of Luxembourg, Dudelange, Luxembourg.
Olga KofanovaIntegrated BioBank of Luxembourg, Dudelange, Luxembourg.
Natalia ErmannDepartment of Psychiatry and Psychotherapy, Laboratory for Clinical Neurochemistry and Neurochemical Dementia Diagnostics, Universitätsklinikum Erlangen, and Friedrich-Alexander Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Germany.
Fay BetsouIntegrated BioBank of Luxembourg, Dudelange, Luxembourg.
Sebastian BrandnerDepartment of Neurosurgery, Universitätsklinikum Erlangen, and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
Barbara MroczkoDepartment of Neurodegeneration Diagnostics, Department of Biochemical Diagnostics, Medical University of Bialystok, University Hospital of Bialystok, Bialystok, Poland.
Kaj BlennowClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Dominik StrapagielBiobank Lab, Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Silvia PaciottiDepartment of Experimental Medicine, University of Perugia, Perugia, Italy.
Jonathan VogelgsangDepartment of Psychiatry and Psychotherapy, University Medical Center Göttingen (UMG), Göttingen, Germany.
Michael H RoehrlDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sandra MendozaNYU Center for Biospecimen Research and Development (CBRD), New York, NY, USA.
Johannes KornhuberDepartment of Psychiatry and Psychotherapy, Laboratory for Clinical Neurochemistry and Neurochemical Dementia Diagnostics, Universitätsklinikum Erlangen, and Friedrich-Alexander Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Germany.
Charlotte TeunissenNeurochemistry Laboratory and Biobank, Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands.
Central Bank of Luxembourg · LUFriedrich-Alexander-Universität Erlangen-Nürnberg · DEMedical University of Białystok · PLAmsterdam UMC Location Vrije Universiteit Amsterdam · NLMemorial Sloan Kettering Cancer Center · USSahlgrenska University Hospital · SEUniversitätsmedizin Göttingen · DEUniversity of Łódź · PLUniversity of Perugia · IT

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Innovative Medicines Initiative Joint Undertaking EMIF grant agreement n° 115372NCI NIH HHS P30 CA008748Polish Ministry of Science and Higher Education DIR/WK/2017/01
6 · The paper itself

Abstract

backgroundIn this study, we tested to which extent possible between-center differences in standardized operating procedures (SOPs) for biobanking of cerebrospinal fluid (CSF) samples influence the homogeneity of the resulting aliquots and, consequently, the concentrations of the centrally analyzed selected Alzheimer's disease biomarkers.

methodsProficiency processing samples (PPSs), prepared by pooling of four individual CSF samples, were sent to 10 participating centers, which were asked to perform aliquoting of the PPSs into two secondary aliquots (SAs) under their local SOPs. The resulting SAs were shipped to the central laboratory, where the concentrations of amyloid beta (Aβ) 1-42, pTau181, and albumin were measured in one run with validated routine analytical methods. Total variability of the concentrations, and its within-center and between-center components, were analyzed with hierarchical regression models.

resultsWe observed neglectable variability in the concentrations of pTau181 and albumin across the centers and the aliquots. In contrast, the variability of the Aβ1-42 concentrations was much larger (overall coefficient of variation 31%), with 28% of the between-laboratory component and 10% of the within-laboratory (i.e., between-aliquot) component. We identified duration of the preparation of the aliquots and the centrifugation force as two potential confounders influencing within-center variability and biomarker concentrations, respectively.

conclusionsProficiency processing schemes provide objective evidence for the most critical preanalytical variables. Standardization of these variables may significantly enhance the quality of the collected biospecimens. Studies utilizing retrospective samples collected under different local SOPs need to consider such differences in the statistical evaluations of the data.

Indexed as

AlbuminsAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersHumansLaboratory Proficiency TestingPeptide FragmentsPhosphorylationReproducibility of Resultstau ProteinsAlbuminsAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersMAPT protein, humanPeptide Fragmentstau ProteinsAlzheimer’s diseaseBiobankingBiomarkerCerebrospinal fluidLaboratory standardization

Identifiers

PMID30153863
PMCPMC6114189
OpenAlexW2889194190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.